Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
Silvia Park; Emma Langley; Jong‐Mu Sun; S. Lockton; Jin Seok Ahn; Anjali Jain; Keunchil Park; Sharat Singh · 2015 · Oncotarget
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
// Silvia Park 1, * , Emma Langley 2, * , Jong-Mu Sun 1 , Steve Lockton 2 , Jin Seok Ahn 1 , Anjali Jain 2 , Keunchil Park 1 , Sharat Singh 2 , Phillip Kim 2 , Myung-Ju Ahn 1 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Prometheus Laboratories Inc, A Nestlé Health Science Company, Department of Research and Development, San Diego, CA, USA * These authors have contributed equally to this work Correspondence to: Myung-Ju Ahn, e-mail: silkahn@skku.edu Phillip Kim, e-mail: pkim@prometheuslabs.co
Abstract by Silvia Park; Emma Langley; Jong‐Mu Sun; S. Lockton; Jin Seok Ahn; Anjali Jain; Keunchil Park; Sharat Singh, Oncotarget (2015) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.18632/oncotarget.5131